When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Guggenheim Analyst Michael Schmidt upgraded Mirati Therapeutics (NASDAQ:MRTX) ratings to Buy from Neutral with a $115 price target. Shares were trading +5.64% at $62.97. The new comes after MRTX submitted a marketing application to the European Union's drug regulator for its investigational inhibitor adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) with a certain mutation who have got a least one prior therapy.